Efficacy and safety of epaminurad, a potent hURAT1 inhibitor, in patients with gout: a randomized, placebo-controlled, dose-finding study

Efficacy and safety of epaminurad, a potent hURAT1 inhibitor, in patients with gout: a randomized, placebo-controlled, dose-finding study

Abstract Background Gout is the most common inflammatory arthritis. Current urate-lowering therapies have limitations, such as adverse drug reactions or limited efficacy. Epaminurad is a novel selective human urate transporter 1 (hURAT1) inhibitor that has been shown to reduce serum urate (sUA) leve...

Full description

Saved in:
Bibliographic Details
Main Authors: Jae-Bum Jun, Hye-Soon Lee, Sang-Hyon Kim, Seung-Geun Lee, Doo-Ho Lim, Jinhyun Kim, Yong-Beom Park, Mie Jin Lim, Seung-Jae Hong, Hyo-Jin Choi, Shin-Seok Lee, Hyun Ah Kim, Jiwon Hwang, Chang-Hee Suh, Seungwoo Han, Jung-Yoon Choe, Wan-Hee Yoo, Jung Soo Song
Format: Article
Language:English
Published: BMC 2025-05-01
Series:Arthritis Research & Therapy
Subjects:
Epaminurad
Gout
Human urate transport 1
hURAT1 inhibitor
Hyperuricemia
URC102
Online Access:https://doi.org/10.1186/s13075-025-03577-w
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13075-025-03577-w

Similar Items